JMP Securities Sticks to Their Buy Rating for KalVista Pharmaceuticals (KALV)
JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on KalVista Pharmaceuticals (KALV – Research Report) today and set a price ...
Blue Owl Capital’s (OWL) Market Outperform Rating Reaffirmed at JMP Securities
JMP Securities reiterated their market outperform rating on shares of Blue Owl Capital (NYSE:OWL – Free Report) in a research ...
JMP Securities Forecasts Strong Price Appreciation for Paylocity (NASDAQ:PCTY) Stock
Paylocity (NASDAQ:PCTY – Free Report) had its target price hoisted by JMP Securities from $250.00 to $270.00 in a research ...
JMP Securities Reaffirms Their Buy Rating on Atricure (ATRC)
In a report released today, Daniel Stauder from JMP Securities reiterated a Buy rating on Atricure (ATRC – Research Report), with a price ...
JMP reiterates AtriCure stock with $60 target, sees growth
JMP Securities maintained its optimistic stance on AtriCure Inc. (NASDAQ:ATRC), reiterating a Market Outperform rating and a $60.00 price target. The firm's analysts highlighted their anticipation for ...
JMP Securities maintains Xometry stock at $42 target
JMP Securities reaffirmed their Market Outperform rating on Xometry Inc (NASDAQ:XMTR) with a steady price target of $42.00. The company, currently trading at $35.67 with a market capitalization of $1.